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ABSTRACT  
Non-alcoholic fatty liver disease (NAFLD) is the commonest liver disorder in 
western industrialized countries (prevalence≈20%), NAFLD represents increase 
fat in hepatocytes (steatosis) visualized, e.g. on ultrasound that cannot be 
attributed to other causes (most commonly alcohol so consider NAFLD if Drink 
male <18u/wk, female <9u). If inflammation is also present (increase LFT, 
typically increase ALT) = non-alcoholic steatohepatitis (NASH). Rule out other 
causes of liver disease and check for associated metabolic disorders (obesity, 
dyslipidemia, diabetes and hypertension). Progression to cirrhosis may occur—
biopsy or elastography may be needed. Risk factors for progression are older age; 
obesity; DM; NASH. Control risk factors; including obesity (bariatric surgery 
helps). Address cardiovascular risk (commonest cause of death). Avoid alcohol 
consumption. No drug is of proven Benefit, though vitamin E may improve 
histology in fibrosis (eg400 iu/d-higher doses Associated with excess mortality). 
Monitor for complications (NASH, cirrhosis, DM). If cirrhotic, screen for HCC with 
ultrasound± AFP twice-yearly. There is no standardized treatment for fatty liver. 
Treating the underlying cause can easily reverse the abnormal changes in the 
liver, provided, it is early in the disease. Homoeopathic remedies like Arsenic 
Album, Nux Vomica, Chelidonium, Cardus m, Apocynum, Lycopodium, Sepia, 
Phosphorous, Digitalis, Bryonia, Helleborus Niger, Ferrum Met, kali Carb, Iris V, 
Natrum Carb and many other medicines are very helpful in the treatment of fatty 
liver symptoms. 
INTRODUCTION
 Fatty liver is the accumulation of 
triglycerides and other fats in the liver cells. The 
amount of fatty acid in the liver depends on the 
balance between the processes of delivery and 
removal. In some patients, fatty liver may be 
accompanied by hepatic inflammation and liver cell 
death (steatohepatitis).[1] 
Potential pathophysiologic mechanisms for fatty 
liver include the following: 
 Decreased mitochondrial fatty acid beta-
oxidation. 
 Increased endogenous fatty acid synthesis or 
enhanced delivery of fatty acids to the liver 
 Deficient incorporation or export of 
triglycerides as very low-density lipoprotein 
(VLDL). 
 Tripodi et al reported that in nonalcoholic 
fatty liver disease (NAFLD), a procoagulant 
imbalance progresses from steatosis to metabolic 
cirrhosis, which may be caused by an increase in 
factor VIII and a reduction of protein C. The 
investigators speculated that this imbalance could 
play a role in the risk for cardiovascular disease and 
liver fibrosis, conditions commonly associated with 
NAFLD. [2] 
 Serum leptin, a cytokine-type peptide 
hormone mainly produced by adipocytes, may play 
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an important role in the pathogenesis of steatosis. 
Steatosis occurs with decreased leptin action, 
whether due to leptin deficiency or resistance. In 
patients with alcoholic liver disease, the serum 
leptin level appears to be independently correlated 
with the grade of steatosis. [3] 
 The condition most commonly associated 
with fatty liver disease is metabolic syndrome. This 
includes conditions such as type II diabetes, obesity, 
and hypertriglyceridemia. 
 Other factors, such as drugs (eg, 
amiodarone, tamoxifen, methotrexate), alcohol, 
metabolic abnormalities (eg, galactosemia, glycogen 
storage diseases, homocystinuria, and tyrosinemia), 
nutritional status (eg, overnutrition, severe 
malnutrition, total parenteral nutrition [TPN], or 
starvation diet), or other health problems (eg, celiac 
sprue and Wilson disease) may contribute to fatty 
liver disease. 
 It has been estimated, as shown in Figure 1, 
that although 90–100% of heavy drinkers show 
evidence of fatty liver, only 10–35% develops 
alcoholic hepatitis and 8–20% develop cirrhosis. [4] 
Figure 1 
 
Progression of alcoholic liver disease in heavy 
drinkers 
Several risk factors may influence the development 
of advanced ALD, including the following: 
 Minimum amounts of alcohol intake associated 
with an increased risk of ALD range from 40 to 
80 g/day for 10-12 years; safe limits for alcohol 
use are not clearly defined. [5] 
 Genetics play a role in alcohol consumption and 
alcoholism; early data suggested a genetic 
predisposition to the development of ALD, 
mostly related to differences in major hepatic 
enzymes involved in the metabolism of alcohol 
(e.g., alcohol dehydrogenase [ADH], 
acetaldehyde dehydrogenase [ALDH], and the 
cytochrome P-450 system [CYP4502E1]). [6] 
 Several studies demonstrate a high prevalence 
of hepatitis C virus (HCV) antibody in patients 
with ALD, as well as iron overload 
 Obesity and dietary habits have been implicated 
in individual susceptibility to ALD 
Stages of Nonalcoholic Fatty Liver Disease 
(NAFLD) [7] 
NAFLD develops in 4 main stages. 
Most people will only ever develop the first stage, 
usually without realizing it. 
In a small number of cases, it can progress and 
eventually lead to liver damage if not detected and 
managed. 
The main stages of NAFLD are: 
1. Simple Fatty Liver (Steatosis) – a largely 
harmless build-up of fat in the liver cells that 
may only be diagnosed during tests carried out 
for another reason 
2. Non-Alcoholic Steatohepatitis (NASH) – a 
more serious form of NAFLD, where the liver 
has become inflamed; this is estimated to affect 
up to 5% of the UK population. 
3. Fibrosis – where persistent 
inflammation causes scar tissue around the 
liver and nearby blood vessels, but the liver is 
still able to function normally. 
4. Cirrhosis – the most severe stage, occurring 
after years of inflammation, where the liver 
shrinks and becomes scarred and lumpy; this 
damage is permanent and can lead to liver 
failure (where your liver stops working 
properly) and liver cancer. 
CLINICAL PRESENTATION 
 Fatty liver occurs commonly after the 
ingestion of a moderate or large amount of alcohol, 
even for a short period of time. Alcohol-induced 
steatosis usually is asymptomatic. Severe fatty 
infiltration of the liver can result in symptoms of 
malaise, weakness, anorexia, nausea, and 
abdominal discomfort. Jaundice is present in 15% 
of patients admitted to the hospital. 
 A thorough clinical history, especially with 
regard to the amount of alcohol consumption, is 
essential for determining the role of alcohol in the 
etiology of abnormal liver test results. History 
obtained from family members may reveal past 
alcohol-related problems. No specific test is 
available to rule out drug-related toxicity, but a 
good review of all concurrent and recent 
medications, including over-the-counter 
medications and alternative treatments, is valuable 
in evaluating the possible causes of abnormal liver 
test results. 
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 The 2010 American Association for the 
Study of Liver Diseases (AASLD) practice guideline 
for alcoholic liver disease (ALD) recommends the 
following for diagnosis: [8] 
 If alcohol abuse or excess is suspected from 
discussion of alcohol use with the patient, 
screen the patient for alcohol abuse using a 
structured questionnaire such as the Alcohol 
Use Disorders Identification Test (AUDIT). 
 If the patient’s history or a screening test 
indicates alcohol abuse, use laboratory testing 
to verify the diagnosis of ALD and rule out other 
considerations. 
 If ALD is confirmed, test for other alcohol-
related organ damage. 
 Most patients with nonalcoholic fatty liver 
disease (NAFLD) are asymptomatic. However, if 
questioned, more than 50% of patients with fatty 
liver or nonalcoholic steatohepatitis (NASH) report 
persistent fatigue, malaise, or upper abdominal 
discomfort. 
 Symptoms of liver disease, such as ascites, 
edema, and jaundice, may arise in patients with 
cirrhosis due to progressive NASH. Laboratory 
abnormalities during blood donations or life 
insurance physical examinations often reveal 
elevated alanine aminotransferase (ALT) levels and 
ultimately lead to the diagnosis of fatty liver 
disease. 
Physical Examination 
 Alcoholic fatty liver may be present in the 
absence of any abnormalities noted on the physical 
examination. Hepatomegaly is common in patients 
who are hospitalized, occurring in over 70% of 
persons with steatosis proven on biopsy. Portal 
hypertension is rare in alcoholic steatosis. 
Extrahepatic effects, such as skeletal muscle 
wasting, cardiomyopathy, pancreatitis, or 
peripheral neuropathy, may be present. 
 Hepatomegaly is also common with NAFLD. 
Splenomegaly and stigmata of portal hypertension 
(eg, ascites, edema, spider angiomas, varices, 
gynecomastia, and menstrual disorders) may occur 
in patients with cirrhosis. Patients with drug-
induced fatty liver may present with rapid 
fulminant liver failure. [9] 
Complications 
 Continued alcohol consumption may result 
in a more advanced form of liver disease, either 
alcoholic hepatitis or cirrhosis. In a study from 
Denmark, using a population-based National 
Registry, investigators noted an increased mortality 
and an increased cancer risk, particularly liver 
cancer, among patients discharged with a diagnosis 
of alcoholic fatty liver. [10] 
 In patients with nonalcoholic fatty liver, 
steatohepatitis may progress to cirrhosis, with 
complications that include variceal bleeding, 
ascites, encephalopathy, and liver failure. The rate 
of progression appears to be worse if more than 1 
liver disease (eg, ALD or chronic viral hepatitis) is 
present. Uncontrolled diabetes and hyper-
triglyceridemia also appear to predict worse 
fibrosis.[11-14] The rate of formation of hepatocellular 
carcinoma appears to be the same as with other 
forms of liver disease, [15]  although NAFLD appears 
to increase the risk for hepatocellular carcinoma in 
patients whose lives are not cirrhotic.[16]  NAFLD 
also appears to be a strong and independent risk 
factor for prediabetes in the general adult 
population. [17] 
Differential Diagnosis 
 The differential diagnosis is broad and 
includes the following conditions: 
 Alcoholic Hepatitis  Hepatitis E 
 Alcoholism  Hepatitis, Viral 
 Alpha1-Antitrypsin 
Deficiency 
 Hyperthyroidism 
 Autoimmune 
Hepatitis 
 Hypothyroidism 
 Celiac Sprue  Isoniazid Hepatotoxicity 
 Cirrhosis  Malabsorption 
 Drug-Induced 
Hepatotoxicity 
 Primary Biliary Cirrhosis 
 Hemochromatosis  Primary Sclerosing 
Cholangitis 
 Hepatitis A  Protein-Losing 
Enteropathy 
 Hepatitis B  Vitamin A Toxicity 
 Hepatitis C  Wilson Disease 
 Hepatitis D  
Steatosis can be observed on histology in the 
following conditions: 
I. Alcohol excess 
II. Starvation 
III. Total parenteral nutrition (TPN) 
IV. Nonalcoholic steatohepatitis (NASH) – A 
diagnosis of NASH can be established only 
when alcohol excess (>10 g/day) can be 
excluded. 
V. Drug-induced liver disease (eg, disease caused 
by valproic acid, tetracycline, antiviral agents 
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such as zidovudine, amiodarone, perhexiline 
maleate, methotrexate, corticosteroids, or 
estrogens). 
VI. Acute fatty liver of pregnancy[18] – This can 
occur during pregnancy and likely results from 
maternal-fetal interactions related to genetic 
abnormalities in mitochondrial beta-oxidation 
of fatty acids 
VII. Metabolic liver disease and other inborn errors 
of metabolism 
VIII. Reye syndrome 
LABORATORY STUDIES 
 Fasting insulin and glucose levels will alert 
the clinician to potential glucose intolerance and 
may lead to more effective therapies. 
 An increase in the levels of 
glutamyltranspeptidase (GGT) may be related to 
alcohol use, but this study lacks specificity and 
sensitivity, and as many as 70% of people who 
abuse alcohol have normal values. 
 In rare cases, patients with alcoholic 
steatosis have severe cholestasis. Ballard et al 
described 5 patients with alcoholic steatosis 
presenting with jaundice. [19] Liver biopsy results in 
all 5 showed severe steatosis and marked 
cholestasis with little hepatic fibrosis. Hepatic 
failure characterized by progressive 
encephalopathy and coagulopathy developed and 
led to death in 2 patients. In a large cooperative 
study of ALD conducted by the Department of 
Veterans Affairs (VA), histologic cholestasis was 
observed in only 19% of patients with alcoholic 
steatosis. 
 Macrocytosis (increased mean cell volume) 
is common in patients with alcoholic liver disease 
(ALD), with a low sensitivity (27-52%) and a high 
specificity (85-91%). Serum carbohydrate-deficient 
transferrin (CDT) is a specific and sensitive test for 
alcoholism in patients whose alcohol intake exceeds 
60 g/day. 
 Hypertriglyceridemia, steatosis, and 
hemolysis (Zieve syndrome) may be associated 
with alcohol abuse. Hyperlipidemia may be present 
in nonalcoholic fatty liver disease (NAFLD). 
Increased triglycerides are common in children and 
in patients with metabolic syndrome. 
 The alkaline phosphatase (ALP) level can be 
elevated in some patients with nonalcoholic 
steatohepatitis (NASH). Usually, it is less than twice 
to 3 times normal. 
 Abnormal levels of aminotransferases (ie, 
aspartate aminotransferase [AST] and alanine 
aminotransferase [ALT]) and bilirubin are found in 
about one third of hospitalized patients with 
alcohol-induced steatosis. In such patients, elevated 
bilirubin levels largely result from an increase in 
the indirect reacting fraction and may reflect 
alcohol-associated hemolysis. AST levels are usually 
higher than ALT. The absolute values of serum AST 
and ALT are almost always less than 500 IU/L. 
 An elevated AST or ALT level may be the 
only abnormality in patients with fatty liver; these 
levels may be elevated as much as 10-fold. 
However, AST and ALT levels may be normal in 
some patients with fatty liver or NASH. In the 
absence of cirrhosis, an AST-to-ALT ratio greater 
than 2 suggests alcohol use, whereas a ratio of less 
than 1 may occur in patients with NASH. 
 Viral serologies for hepatitis C should be 
ordered to identify or exclude viral infection. In 
addition, iron levels and total iron-binding capacity 
(TIBC) should be measured, and abnormal results 
from liver function tests should be evaluated as 
indicated. 
 Elevations in serum ferritin or iron, 
decreased transferrin saturation, or both may occur 
in patients with NASH. Although iron overload 
occurs in a small proportion of patients with NASH, 
these patients have more severe disease.  Evidence 
exists that a serum ferritin greater than 1.5 times 
the upper limit of the normal range in patients with 
NAFLD is associated with a higher NAFLD activity 
score (and thus, NASH) and with advanced hepatic 
fibrosis.[20] An iron index score may be ordered on a 
liver biopsy specimen to evaluate for phlebotomy. 
Hemochromatosis gene testing is recommended 
when the ferritin is significantly elevated. Simply 
eliminating dietary iron has been shown to improve 
fatty liver. 
 Autoimmune markers, such as antinuclear 
antibody (ANA) and anti–smooth muscle antibody 
(ASMA), are often slightly elevated in NASH. 
Positive antibodies are associated with more severe 
fibrosis levels. In the appropriate clinical setting, 
serum protein electrophoresis (SPEP) and anti–
liver-kidney antibody may lead to a diagnosis of 
autoimmune liver disease. 
 Often, a clinical picture of obesity, 
hypertriglyceridemia, and elevated transaminases 
is enough to allow the clinician to conclude that a 
patient has NASH. However, underlying alcohol or 
other drug ingestion, as well as smoldering 
autoimmune disease or hemochromatosis, must be 
ruled out. Referral to a hepatologist with or without 
liver biopsy may help in staging and prognosis. 
 Serum beta-trophin level may have 
potential as a new marker for noninvasive 
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evaluation of NAFLD and liver fibrosis, according to 
a study by Cengiz et al.[21]  In their cohort of 69 
patients with NAFLD and 69 healthy control 
subjects, serum beta-trophin levels were lower in 
the NAFLD group; those with mild fibrosis had 
elevated serum beta-trophin levels compared to 
those with significant fibrosis. In multivariate and 
ROC (receiver operating characteristic) analyses, 
serum beta-trophin was, respectively, an 
independent predictor of significant fibrosis and 
was statistically significant in identifying significant 
fibrosis.[21] 
 In a separate study, Abdel-Razik et al 
proposed mean platelet volume and the neutrophil-
lymphocyte ratio as novel inexpensive and simple 
markers of inflammation to predict fibrosis in 
patients with NAFLD as well as to predict the 
presence of NASH. The investigators noted that 
patients with NASH had elevated levels of mean 
platelet volume and neutrophil-lymphocyte ratio 
compared to those without NASH, as well as in 
patients with advanced fibrosis compared to those 
with early fibrosis. [22] 
Ultrasonography, CT, and MRI 
 Noninvasive studies such as 
Ultrasonography (US), computed tomography (CT), 
and magnetic resonance imaging (MRI) are useful in 
helping to establish a diagnosis of steatosis, as well 
as in finding evidence for portal hypertension; these 
imaging tests are also helpful in ruling out biliary 
dilation from other disorders (e.g., 
Choledocholithiasis) in patients with a cholestatic 
pattern of liver test result abnormalities. 
 However, these modalities can neither 
define the cause of steatosis nor reliably distinguish 
between benign steatosis and steatohepatitis. 
Benign steatosis may be focal or diffuse, whereas 
steatohepatitis is usually diffuse. 
 In patients with alcoholic steatosis, the liver 
appears diffusely echogenic on US. In patients with 
nonalcoholic fatty liver disease (NAFLD), the liver is 
hyperechogenic or bright. Steatosis is detected only 
when substantial (≥ 30%) fatty change is present. 
Studies in patients who are about to undergo 
gastric bypass surgery indicate that US has a 93% 
predictive value for NAFLD, with an accuracy of 
76%. Patients with steatosis on US have a higher 
incidence of coronary artery disease and should 
undergo cardiac evaluation if suspicious symptoms 
are present. [23] 
 The mean CT (Hounsfield unit) count is 
lower in the liver than in the spleen. CT scans may 
be used to monitor the course of the disease on 
successive scans. Focal fatty lesions may be 
identified by dual-energy CT scans that 
demonstrate increased attenuation with increasing 
energy and no change in normal. 
 MRI may be useful for excluding fatty 
infiltration. Phase-contrast imaging correlates with 
the quantitative assessment of fatty infiltration 
across the entire range of liver disease. Loss of 
intensity on T1-weighted images may be useful in 
identifying focal fat. 
Liver Biopsy and Histopathologic Examination 
 Liver biopsy and histopathologic 
examination are important components of the 
diagnostic evaluation in patients with suspected 
alcoholic liver disease (ALD). They are the most 
sensitive and specific means of evaluating the 
degree of liver cell injury and hepatic fibrosis. 
Several reasons justify obtaining a liver biopsy in 
patients with ALD, including the following: 
 Confirming the diagnosis 
 Excluding other unsuspected causes of liver 
disease 
 Assessing the extent of liver damage 
 Defining the prognosis 
 In making the decision on whether to 
perform a biopsy, it is important to consider the 
strength of the clinical diagnosis and the role that 
the biopsy findings would have in guiding 
therapeutic options. For patients who are unlikely 
to receive specific treatments or who have 
conditions that make a biopsy unsafe, the 2010 ALD 
guideline recommends including procedure risk in 
the biopsy decision.8 
 A liver biopsy and histopathologic 
examination are required to establish the diagnosis 
of nonalcoholic fatty liver disease (NAFLD). The 
diagnosis should be considered in all patients with 
unexplained elevations in serum aminotransferases 
(eg, with findings negative for viral markers or 
autoantibodies or with no history of alcohol use). 
The Brunt classification is the standard used to 
report NAFLD and nonalcoholic steatohepatitis 
(NASH) biopsy specimens. [24] 
HISTOLOGIC FINDINGS 
 Histologically, fatty liver is characterized by 
fat accumulation, which is most prominent in the 
pericentral (centrilobular) zone. Macrovesicular 
steatosis is the rule; hepatocytes containing 1 or 
more large fat droplets displace the nucleus to an 
eccentric position. Occasional lipid release from 
rupture of distended hepatocytes may produce a 
mild localized inflammatory response 
(lipogranulomas) composed predominantly of 
macrophages and occasional lymphocytes. 
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 Although infiltration of liver with 
inflammatory cells typically is not prominent in 
patients with steatosis alone, in some instances, 
fibrosis around terminal venules (i.e., perivenular 
fibrosis) or hepatocytes (ie, pericellular fibrosis) 
has been noted. Early changes observed with the 
electron microscope include accumulation of 
membrane-bound fat droplets, proliferation of 
smooth endoplasmic reticulum, and gradual 
distortion of mitochondria. Microvesicular steatosis 
also is being recognized with increasing frequency. 
 Alcoholic foamy degeneration 
(microvesicular fatty change) was the term used by 
Uchida et al to describe a clinical syndrome in 
people with chronic alcoholism. [25] The syndrome is 
characterized by jaundice and hyperlipidemia and 
is associated with striking microvesicular steatosis 
and abundant giant mitochondria observed on liver 
biopsy. 
 Specific histologic findings in NAFLD or 
NASH include the following: 
 Steatosis, which usually is macrovesicular but 
may be microvesicular or mixed 
 Inflammatory infiltrates consisting of mixed 
neutrophilic and mononuclear cells, usually 
without portal infiltrates (in contrast to 
hepatitis C) 
 Ballooning degeneration 
 Fibrosis 
 The first 3 findings are used to calculate the 
NAFLD activity score, which is determined on a 
scale of 0 to 8. The stage of disease is determined by 
the NAFLD activity score and the amount of fibrosis 
present. 
HOMOEOPATHIC TREATMENT 
 There are following remedies which are 
helpful in the treatment of fatty liver symptoms: 
Bryonia  [26,27] 
 When there are stitching pains in the right 
hypochondriac region, Bryonia is the first remedy 
to be thought of, though for these pains we have 
other remedies, such as Chelidonium and Kali 
carbonicum. Under Bryonia the liver is swollen, 
congested and inflamed; the pains in the 
hypochondriac region are worse from any motion, 
and better from lying on the right side, which 
lessens the motion of the parts when breathing. It is 
one of the chief remedies for jaundice brought on by 
a fit of anger.  
Chelidonium[28-30] 
 Chelidonium is distinguished by the 
character of the stools. Bryonia is pre-eminently a 
gastro-hepatic remedy, and has pain in right 
shoulder, giddiness, skin and eyes slightly yellow. 
Hughes says it hardly reaches true hepatitis. 
 The liver symptoms of Chelidonium are very 
prominent. There is soreness and stitching pains in 
the region of the liver, but the keynote for this drug 
in hepatic diseases is a pain under the angle of the 
right shoulder blade, which may extend to the chest, 
stomach, or hypochondrium; there is swelling of the 
liver, chilliness, fever, jaundice, yellow coated 
tongue, bitter taste and a craving for acids and sour 
things, such as pickles and vinegar. 
Mercurius. [31,26] 
 This remedy has much sensitiveness and 
dull pain in the region of the liver; the patient 
cannot lie on the right side. The liver is enlarged. 
The skin and conjunctiva are jaundiced. The stools 
are either clay-colored from absence of bile, or 
yellowish-green bilious stools passed with a great 
deal of tenesmus. There is a yellowish white coated 
tongue which takes the imprint of the teeth and 
there is a foetid breath, loss of appetite and 
depression of spirits. 
Podophyllum[32,33] 
 The principal use of Podophyllum is in liver 
affections. Primarily, it induces a large flow of bile, 
and, secondarily, great torpidity, followed by 
jaundice. It is indicated in torpid or chronically 
congested liver, when diarrhea is present. The liver 
is swollen and sensitive, the face and eyes are 
yellow and there is a bad taste in the mouth. The 
tongue is coated white or yellow and the bile may 
form gall stones. 
Digitalis. [26,31] 
 When jaundice arises from cardiac diseases, 
Digitalis may be the remedy. There is no retention 
of bile, nor obstruction of the ducts, but the jaundice 
is due to the fact that the liver does not take from 
the blood the elements which go to form bile. There 
is present drowsiness, bitter taste, soreness, 
enlargement and bruised feeling in the region of the 
liver. 
Myricacerifera [34] 
 Myrica is an important liver remedy. There 
is first despondency and also jaundice due to 
imperfect formation of bile in the liver, and not to 
any obstruction, comparing here with Digitalis. 
There is dull headache, worse in the morning, the 
eyes have a dingy, dirty, yellowish hue, the tongue is 
coated yellow. 
Nux vomica[35,36] 
 In liver affections occurring in those who 
have indulged to excess in alcoholic liquors, highly 
seasoned food, quinine, or in those who have 
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abused themselves with purgatives, Nux is the first 
remedy to be thought of. The liver is swollen hard 
and sensitive to the touch and pressure of clothing 
is uncomfortable. The first remedy in cirrhosis of 
the liver. Colic may be present. 
Lycopodium[37] 
 Lycopodium acts powerfully on the liver. 
The region of the liver is sensitive to the touch, and 
there is a feeling of tension in it, a feeling as if a cord 
were tied about the waist. Cirrhosis. The pains are 
dull and aching instead of sharp and lancinating, as 
under Chelidonium. Fullness in the stomach after 
eating a small quantity. 
Carduus marianus[31] 
 This remedy is indicated in jaundice with 
dull headache, bitter taste, white tongue with red 
edges, nausea and vomiting of a greenish fluid. 
There is an uncomfortable fullness in the region of 
the liver, the stools are bilious and the urine golden 
yellow; there is sensitiveness in the epigastrium 
and right hypochondrium. Burnett regards a dark 
brownish patch over the lower part of the sternum 
as a useful hint for Carduus, and in such cases he 
observes that both the liver and heart are at fault. 
The presence of "liver spot seems to be a special 
indication for the remedy. 
Sulphur[36,26] 
 Sulphur is suitable to chronic affections of 
the liver; it increases the flow of bile and there is 
much pain and soreness in the liver. Sulphur often 
completes the cure commenced by Nux. Liver 
complaints from abuse of mercury will oftentimes 
call for Sulphur. If the stools are colorless and if 
much jaundice or ascites be present Sulphur is 
contra-indicated. Lachesis, however, has jaundice, 
as do all snake poisons, and is useful in the enlarged 
livers of drunkards, with tenderness on pressure 
and throbbing in the right side. 
Phosphorus[38] 
 Phosphorus is homoeopathic to fatty 
degeneration of the liver, with well-marked 
soreness and jaundice. The stools are grayish white. 
Cirrhosis and atrophy may also call for Phosphorus. 
The jaundice is indicative of organic diseases, and 
the remedy is a useful one in malignant diseases of 
the liver. Digitalis has also been recommended in 
acute yellow atrophy. Jaundice accompanying 
pneumonia may also call for Phosphorus. 
Taraxacum[39-41] 
 This is a decided liver remedy, and the 
indications are a mapped tongue and a bitter taste 
in the mouth, chilliness after eating, pain and 
soreness in the region of the liver and bilious 
diarrhea. Kali bichromicum also has a mapped 
tongue. Yucca filamentosa has a pain going from the 
upper region of the liver to the back and a bad taste 
in the mouth. The stools are loose and bilious, 
accompanied with much flatus. 
CONCLUSION 
 Homeopathy is one of the most popular 
holistic systems of medicine. The selection of 
remedy is based upon the theory of 
individualization and symptoms similarity by using 
holistic approach. This is the only way through 
which a state of complete health can be regained by 
removing all the sign and symptoms from which the 
patient is suffering. The aim of homeopathy is not 
only to treat fatty liver symptoms but to address its 
underlying cause and individual susceptibility. As 
far as therapeutic medication is concerned, several 
remedies are available to treat fatty liver symptoms 
that can be selected on the basis of cause, 
sensations and modalities of the complaints. 
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